Herranz Lab
banner
herranzlab.bsky.social
Herranz Lab
@herranzlab.bsky.social
Associate Professor working on Leukemia @rutgerscancer.bsky.social | PharmD @ucm.es | PhD @CNIOStopCancer.bsky.social | Postdoc @columbiauniversity.bsky.social. Posts=my views alone.
Cite them as referencing to Product#XX or Other Significant Product#YY…add bold, line breaks, etc with html tags.
But overall, not sure who likes this new format tbh…
February 1, 2026 at 6:15 PM
Reposted by Herranz Lab
Here is the curve for new and competitive renewal (Type 1 and Type 2) awards.

This reveals that only very few (42) new and competitive renewal awards have been made thus far in fiscal year 2026.

This compares with more than 1200 through the same date in previous fiscal years.

3/6
January 8, 2026 at 4:44 PM
🤣
January 4, 2026 at 2:23 PM
January 1, 2026 at 11:23 PM
Thanks so much to the funding agencies that supported these studies, most prominently @ludwigcancer.bsky.social and The V Foundation.

Now, may the review Gods be with us! 🤞
December 24, 2025 at 2:35 AM
We believe the potential implications of our findings are huge, not only in leukemia, but also in immune-related diseases and hypercholesterolemia.
This was done as an extremely enjoyable joint collaboration with Raphael Morscher's Lab at the University of Zurich.
December 24, 2025 at 2:31 AM
Even more fascinating, this phenotype was linked to a translational regulatory axis between histidine levels and cholesterol. Indeed, cholesterol supplementation in the diet partially rescued the antileukemic effects of diets without histidine!
December 24, 2025 at 2:29 AM
We verified dose-dependent effects of dietary histidine in mouse T-ALL progression, and histidine restriction also showed therapeutic effects in human T-ALL PDXs.
Moreover, histidine restriction led to a massive block in normal T-cell development.
December 24, 2025 at 2:28 AM